Icon

PLUVICTO (nda215833)- (27mCi/ML)

LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN NOVARTIS
27mCi/ML
No No
2035-Nov-12 2027-Mar-23
None None
None No
PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
0 0 0
Total Other Developers None
Drugs with Suitability No
27mCi/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.